


CORRECTIONS

Incorrect Data in the Abstract and a Figure Caption: In the Original Investigation titled “Analysis of Plasma Cell-Free DNA By Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer,” published online May 9, 2019, in *JAMA Oncology,* 1 errors occurred in both the Abstract and a Figure caption. In the Results portions of the Abstract, the numerator, denominator, and percentage were incorrect in the second sentence of the Abstract, which should have read as follows: “Preoperatively, ctDNA was detectable in 108 of 122 patients (88.5%).” In addition, the range for the mean time reported for circulating tumor DNA (ctDNA) was incorrect in the second sentence of Figure 3’s caption; the sentence should have read as follows: “The mean time from surgery to relapse detection was 5.5 months (range, 0.4-17.7 months) for ctDNA and 14.2 months (range, 5.9-31.1 months for CT).” This article was corrected online.


Errors in Data Presentation in Text, Figures, Table, and eTables: In the Original Investigation by Hilal et al titled “Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration,” published online May 2, 2019, in *JAMA Oncology,* 1 there were errors in the number of US Food and Drug Administration approvals and trials described in the Abstract, Results, Discussion, and Conclusions sections; Figures; Table, and eTables. In Figure 1, 48 anticancer drug approvals were excluded, 95 drug approvals were reviewed, and 79 approvals were based on randomized clinical trials with optimal controls. The suboptimal control bars for genitourinary and lung/head and neck tumors in Figure 2 should reach 4% and 2%, respectively. In the Table, the study by Hussain et al has been added and the study by Kim et al has been deleted. In Supplement 2, the PROSPER trial was deleted from eTable 1 and added to eTable 2. The ALTA trial was deleted from eTable 2. This article was corrected online.

1. Hilal T, Sonbol MB, Prasad V. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration [published online May 2, 2019]. *JAMA Oncol.* doi:10.1001/jamaoncol.2019.0167

Correction to Conflict of Interest Disclosure: In the Viewpoint titled “Tumor Mutation Burden—From Hopes to Doubts,” published online May 30, 2019, the Conflict of Interest Disclosures section was missing a disclosure statement for Dr Addeo. This article was corrected online.


Error in a Data Point in Table 3: In the Original Investigation titled “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies,” published in the April 2015 issue of *JAMA Oncology,* there was a typo in one of the data points of Table 3. This article was corrected online.


Erroneous Cohort Totals in Abstract: In the Original Investigation titled, “Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births,” erroneous cohort totals for children without any birth defects, children with chromosomal anomalies, and children with nonchromosomal birth defects were added late in the editorial process and included in initial publication. These have been deleted, and correct population information is available in Table 1. Typographical errors in the Results section of the Abstract and the Methods section of the article body have also been fixed. This article was corrected online.


Error in Title: In the Original Investigation titled, “Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate,” which published online June 27, 2019, in *JAMA Oncology,* there was an error in the title. The correct title is “Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.” This article was corrected online.